Neurocrine Bio. stock price target raised to $169 by Jefferies

Neurocrine Biosciences (NBIX) saw its price target raised by Jefferies to $169, among other analyst upgrades, following positive Phase 2 SAVITRI trial results for its major depressive disorder (MDD) drug, osavampator (NBI-845). The 1mg dose demonstrated significant efficacy and tolerable safety, comparable to esketamine, and will proceed to Phase 3. Despite Jefferies modeling $450 million in peak sales with a 40% probability, questions persist about efficacy holding up in Phase 3 due to an inverse dose response and the typical shrinkage of effect sizes between trial phases.

Analysis

Neurocrine Biosciences (NBIX) is seeing positive sentiment and analyst upgrades following the presentation of its Phase 2 SAVITRI trial data for osavampator in major depressive disorder. The results for the 1mg dose were compelling, showing efficacy comparable to esketamine's Phase 3 data, with placebo-adjusted MADRS scores of -3 to -4.3, and a tolerable safety profile that notably lacked mentions of dissociation or seizures. This has prompted Jefferies to raise its price target to $169, with Stifel and UBS also issuing bullish targets of $174 and $188, respectively. This clinical progress is set against a backdrop of strong company performance, including an 18.42% LTM revenue growth and a nearly 30% stock price increase in the past six months. However, significant risks persist. The trial data revealed an inverse dose response, as the 3mg dose was not statistically significant, and there is a well-known risk of efficacy diminishing between Phase 2 and the larger Phase 3 studies. Jefferies quantifies this by modeling $450 million in peak sales but assigning only a 40% probability of success. The long development timeline, with Phase 3 completion not expected until July 2027, combined with a dissenting Market Perform rating from BMO Capital ($124 PT), highlights the speculative and long-term nature of this potential value driver.

Key Decisions for Investors

• The positive Phase 2 data supports a bullish thesis, but investors must acknowledge the long-term horizon, as the primary catalyst from Phase 3 data is not expected until July 2027.
• Closely monitor the key clinical risks heading into Phase 3, specifically the unresolved inverse dose-response and the potential for diminished efficacy, which could significantly alter the drug's 40% probability of success.
• Given the stock's recent 30% run-up, investors should weigh the current valuation against the risk-adjusted potential of osavampator, as reflected in the wide dispersion of analyst price targets from $124 to $188.